What is Evommune?
Evommune operates at the intersection of advanced immunology and therapeutic innovation. The company is dedicated to developing targeted treatments that transcend mere symptom management, focusing instead on the underlying biological drivers of chronic inflammatory diseases. By leveraging sophisticated research methodologies, Evommune aims to fill critical gaps in the current treatment landscape, providing novel solutions for patients with limited therapeutic options. Its market position is defined by a commitment to precision medicine and high-impact clinical outcomes.
How much funding has Evommune raised?
Evommune has raised a total of $185M across 3 funding rounds:
Angel/Seed
$12.5M
Series B
$57.5M
Series C
$115M
Angel/Seed (2020): $12.5M with participation from PIVOTAL BIOVENTURE PARTNERS LLC
Series B (2023): $57.5M led by Verition Fund Management, Arix Bioscience, and Symbiosis Group
Series C (2024): $115M supported by RA Capital Management, Longwood Fund, Andera Partners, Beiersdorf, Marshall Wace, Sectoral Asset Management, Avego, RTW Investments, FemHealth Ventures, Verition Fund Management, B Capital Group, Pivotal Bioventure Partners, Amplitude Ventures, and ADAR1 Capital Management
Key Investors in Evommune
RA Capital Management
A multi-stage investment manager utilizing evidence-based analysis through its TechAtlas think tank to support innovation in drug development and medical diagnostics.
Longwood Fund
A Boston-based firm that actively co-founds and builds science-based companies, leveraging deep expertise to bring transformative therapies from the laboratory to the clinic.
Andera Partners
A Paris-based investment firm with a dedicated life sciences team that manages extensive capital to support European and U.S. biotech and medtech innovation.
What's next for Evommune?
Following this major strategic investment, Evommune is poised to transition into a more aggressive phase of clinical execution. The capital will likely be deployed to scale its research and development infrastructure, support ongoing clinical trials, and potentially expand its therapeutic pipeline. As the company matures, the focus will shift toward validating its lead candidates in human trials, thereby de-risking its portfolio and enhancing its value proposition for future commercialization or strategic partnerships within the global biopharmaceutical sector.
See full Evommune company page
